Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2200 participants.

Also called NCT02642419

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,200 participants (planned count) (from the registry)
Sponsor
Japan Cardiovascular Research Foundation (from the registry)
Registry
  • NCT NCT02642419
Other papers using this trial's data
  • Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease The New England journal of medicine, 2019-09-19 DOI, PubMed 31475793 PubMed links an erratum for this paper. Erratum: PMID 34670061
  • Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation Heart (British Cardiac Society), 2021-11 DOI, PubMed 34261738
  • Risk prediction score for clinical outcome in atrial fibrillation and stable coronary artery disease Open heart, 2023-05 DOI, PubMed 37173099, PMC10186465 In the PMC Open Access subset under CC BY-NC.
  • Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial JAMA cardiology, 2022-08-01 DOI, PubMed 35704345, PMC9201742 Not in the PMC Open Access subset.
  • Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis American heart journal, 2021-06 DOI, PubMed 33657403
  • The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial BMC medicine, 2022-02-25 DOI, PubMed 35209924, PMC8876785 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02642419. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study
Acronym
AFIRE
Intervention (Drug)
Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)
Intervention (Drug)
Rivaroxaban
Lead sponsor
Japan Cardiovascular Research Foundation (class: other)

Record details

Record id
cardio:ct-nct02642419
Content hash
3acaa618119bdacbe4db13b95a2ce3d9d33a959ab4650ecb0478df61c31ecb70